• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Embecta Corp.

    5/30/25 1:19:35 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care
    Get the next $EMBC alert in real time by email
    SD 1 a05292025formsd.htm SD Document

          
     
     
    United States
    Securities and Exchange Commission
    Washington, D.C. 20549
     
    FORM SD
     
    SPECIALIZED DISCLOSURE REPORT
     
    Embecta Corp.
    (Exact name of registrant as specified in its charter)
     
     
    Delaware001-4118687-1583942
    (State or other jurisdiction of
    incorporation or organization)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
    300 Kimball Drive, Suite 300
    Parsippany, New Jersey
    07054
    (Address of principal executive offices)
    (Zip Code)
    Shaun Curtis
    (862) 401-0000

    (Name and telephone number, including area code, of the person to contact in connection with this report.)
     
    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
    ☒    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.
     
     
     



     
    Section 1 – Conflict Minerals Disclosure
    Item 1.01    Conflict Minerals Disclosure and Report
    As contemplated by Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and Form SD, a Conflict Minerals Report is provided as an Exhibit to this Form SD and is available at the following Internet website: https://investors.embecta.com/financials-filings/sec-filings. The information contained on our website is not incorporated by reference into this Form SD or our Conflict Minerals Report and should not be considered part of this Form SD or the Conflict Minerals Report.
    Information concerning tin, tantalum, tungsten, or gold from recycled or scrap sources that may be contained in our in-scope products is included in the Conflict Minerals Report and is incorporated in this Form SD by reference.
    Item  1.02    Exhibit
    The Conflict Minerals Report contemplated by Item 1.01 is filed as Exhibit 1.01 to this Form SD.
    Section 2 – Exhibits
    Item  2.01    Exhibits
    Exhibit 1.01 – Conflict Minerals Report for the calendar year ended December 31, 2024.
     



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
    Embecta Corp.
    (Registrant)



    By:

    /s/ Shaun Curtis______________

    May 30, 2025
    Name:Shaun Curtis
    Title:SVP, Global Manufacturing and Supply Chain

     



    EXHIBIT INDEX
     
    Exhibit
    Description
    1.01
    Conflict Minerals Report for the calendar year ended December 31, 2024.

    Get the next $EMBC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EMBC

    DatePrice TargetRatingAnalyst
    4/10/2025$15.00Neutral
    Mizuho
    12/2/2024$13.00 → $20.00Underweight → Equal-Weight
    Morgan Stanley
    11/27/2024$26.00Neutral → Buy
    BTIG Research
    10/20/2023Peer Perform
    Wolfe Research
    1/6/2023$28.00Equal-Weight → Underweight
    Morgan Stanley
    9/8/2022Neutral
    BTIG Research
    8/1/2022$33.00Equal-Weight
    Morgan Stanley
    6/21/2022$25.00Underperform
    BofA Securities
    More analyst ratings

    $EMBC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • embecta to Participate in Investor Events

      PARSIPPANY, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events: 2025 Goldman Sachs Tenth Annual Leveraged Finance and Credit Conference Management will host one-on-one investor meetings on Thursday, May 29, 2025, at Waldorf Astoria Monarch Beach Resort & Club, Dana Point, CA. 2025 Jefferies Global Healthcare Conference Management will host a fireside session on Thursday, June 5, 2025, at 4:55 p.m. EDT, at the Marriott Marquis, New York City. 2025 Goldma

      5/27/25 5:00:00 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • embecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor Day

      PARSIPPANY, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta"; "The Company") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host its inaugural Analyst and Investor Day today to showcase its phased approach for value creation and present its long range financial plan ("LRP"). "Our Investor Day will provide a comprehensive view of our roadmap for transitioning embecta to growth. We look forward to sharing how we are positioning embecta for long-term success in an evolving healthcare landscape," said Dev Kurdikar, President and Chief Executive Officer. "Today, we reiterate our commitment to maintaining our leadership in insulin i

      5/22/25 6:30:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025. "This quarter's financial results were once again slightly ahead of our prior expectations, as our teams executed well, which included driving an acceleration in our free-cash flow generation, thereby allowing us to continue to repay debt and create additional balance sheet flexibility," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdikar added, "In this challenging operating environment, we are raising key profitability

      5/9/25 6:30:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    $EMBC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Melcher David F bought $105,995 worth of shares (10,000 units at $10.60), increasing direct ownership by 13% to 86,681 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      5/23/25 4:35:56 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SVP and CFO Elguicze Jacob covered exercise/tax liability with 4,948 shares, decreasing direct ownership by 3% to 168,599 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      4/8/25 4:25:00 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SVP, Global Manuf./Sup. Chain Curtis Shaun covered exercise/tax liability with 3,249 shares, decreasing direct ownership by 5% to 59,061 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      4/8/25 4:22:22 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    $EMBC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Embecta Corp. with a new price target

      Mizuho initiated coverage of Embecta Corp. with a rating of Neutral and set a new price target of $15.00

      4/10/25 12:41:09 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Embecta Corp. from Underweight to Equal-Weight and set a new price target of $20.00 from $13.00 previously

      12/2/24 6:56:10 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. upgraded by BTIG Research with a new price target

      BTIG Research upgraded Embecta Corp. from Neutral to Buy and set a new price target of $26.00

      11/27/24 7:22:14 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    $EMBC
    SEC Filings

    See more
    • SEC Form SD filed by Embecta Corp.

      SD - Embecta Corp. (0001872789) (Filer)

      5/30/25 1:19:35 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Embecta Corp. (0001872789) (Filer)

      5/22/25 8:55:41 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.

      SCHEDULE 13G/A - Embecta Corp. (0001872789) (Subject)

      5/15/25 10:44:06 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care